Company intelligence / Profile preview

Werewolf Therapeutics, Inc.

Watertown, Massachusetts, United Stateswerewolftx.com ↗

Ownership: Public · HOWL
Development stage: Phase 1

Overview

WTX-124 (IL-2 INDUKINE) has shown promising durable anti-tumor activity with unprecedented tolerability for cytokine therapeutics in Phase 1/1b trials. WTX-330 (IL-12 INDUKINE) is advancing to Phase 1/2 trials in Q1 2025. Both programs have demonstrated improved therapeutic index compared to traditional cytokine therapies.

Therapeutic areas: GastroenterologyOncology
Modalities: Conditionally activated biologicsINDUKINE™ molecules (engineered cytokines)
Industry: Biotech

Drug pipeline

7 assets

WTX-330

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $46.9M
Total revenue: $21M
Enterprise value: $24.9M

Beyond the preview

Go deeper on Werewolf Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Werewolf Therapeutics, Inc..

Explore the full profile